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Abstract
Liver fibrosis is a common histological process to develop into cirrhosis in various chronic liver
diseases including chronic hepatitis and fatty liver. Therefore anti-liver fibrosis is very important
strategy to treat chronic liver diseases. Fuzheng Huayu (FZHY), a preparation containing herbs such
as Radix Salvia Miltiorrhizae, Cordyceps, Semen Persicae, was formulated on the basis of Chinese
medicine theory in treating liver fibrosis and was approved. Pharmacological studies and clinical
trials demonstrate that FZHY has a significant effect against liver fibrosis and that many of the
pharmacological actions are attributable to the effect. This article reviews the effects and actions
of FZHY, in particular the effects observed from clinical trials in treating liver fibrosis caused by
chronic hepatitis B and the actions on inhibition of hepatic stellate cell activation, protection of
hepatocytes and inhibition of hepatic sinusoidal capillarization. This article also reviews the
coordinated effects of the constituent herbs of FZHY and the actions of their active compounds
such as salvianonic acid B (SA-B) on liver fibrosis.
Background
Liver fibrosis is characterized by overproduction and irreg-
ular deposition of extracellular matrix (ECM) in liver tis-
sues [1], leading to the distortion of hepatic
microstructure and liver dysfunction. The structural
changes include hepatic sinusoid capillarization, portal
area and liver lobule fibrosis and alterations in microvas-
cular structure. The dysfunction is manifested by the defi-
ciency of liver function and portal hypertension. The main
causes of liver fibrosis include hepatitis viruses, alcohol,
drugs, toxins, schistosome, nonalcoholic steatohepatitis
(NASH), cholestasis and autoimmune liver disease. Their
persistent insults on the liver activate hepatic stellate cells
(HSCs) in the sinusoid, resulting in the imbalance of ECM
metabolism. For example, ECM overproduction may
cause over deposition in liver and hepatic structure
remodeling. Liver fibrosis can progress into liver cirrhosis
which causes further hepatocellular dysfunction and
increases intrahepatic resistance to blood flow, leading to
hepatic insufficiency and portal hypertension. Liver cir-
rhosis is the seventh leading cause of disease-related death
in the United States [2].
Liver fibrosis was considered to be a passive and irreversi-
ble process due to the collapse of the hepatic parenchyma
and its substitution with ECM components [3]. However,
the reversibility of liver fibrosis has now been demon-
strated both in patients and animal models [4].
Antifibrotic strategies against liver fibrosis include early
intervention or control of etiologies, hepatic inflamma-
tion prevention and regulation of hepatic ECM metabo-
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lism and stellate cell activation. Viral hepatitis is the most
important antecedent factor for liver fibrosis. Tremendous
progress has been made in targeted antiviral treatment in
recent years. Recent evidence showed that liver fibrosis
could regress with effective antiviral treatment. However,
even removal of initial fibrotic stimulus such as viruses
may slow fibrosis progression but does not stop the pro-
gression entirely [5]. Treatment to improve ECM metabo-
lism is still needed for antiviral treatment. Animal
experiments suggest that some fibrosis may persist for
very long periods after liver injuries, particularly if the
remaining collagen is cross-linked by tissue transglutami-
nase and thus more resistant to metalloproteinase. Effi-
cacy of antiviral treatment is limited in fibrotic patients
suffering from viral infection, in particular hepatitis B
patients. Patients with lowered viral replication may have
hepatic inflammation which can still develop into cirrho-
sis through fibrosis. In patients with hepatitis C virus, the
severity of liver fibrosis is not necessarily correlated with
viral loads or viral genotypes affecting the response of
antiviral treatment.
From the studies on liver fibrosis in recent decades [6], we
understand that the activation of HSC is a crucial cellular
change in liver fibrosis [7]. The regulation of the activa-
tion of HSCs has been partially elucidated [8]. The fibro-
genetic factors including free radicals, ECM environment
and cytokines, in particular transforming growth factor
beta one (TGF-β1) were only found in recent years. While
effective treatment which targets these specific factors is
still not ready. Chinese medicine has significantly contrib-
uted to antifibrotic treatment.
Antifibrotic treatment with Chinese medicinal herbs
Although Chinese medicine does not have the concept of
liver fibrosis, its does treat chronic liver diseases effec-
tively. Research on liver fibrosis in Chinese medicine has
gone through three stages: (1) Clinical exploration (1950s
to 1970s). Chinese medicine considers liver fibrosis as
Xietong  (Hypochondriac pain), Zhengjia  (mass in the
abdomen) and Guzhang (Tympanites). The basic patho-
genesis of liver fibrosis is regarded as deficiency of healthy
energy and stagnation of blood and treatment of liver
fibrosis is to activate blood stasis and invigorate spleen
according to Chinese medicine syndrome differentiation.
Some frequently used formulas include Taohong decoc-
tion consisting of Semen Persicae (Taoren), Flos Carthami
(Honghua),  Rhizoma Ligustici Chuanxiong (Chuanxiong),
Radix Angelicae Sinensis (Danggui) and Radix Clematidis
(Weilingxian), and Xiayuxue decoction consisting of Radix
et Rhizoma Rhei (Dahuang),  Semen Persicae and  Eupoly-
phaga seu Opisthoplatia (Zhechong) [9]. (2) Experimental
investigation (late 1970s to early 1990s). The efficacy of
Chinese medicine against liver fibrosis was investigated
with animal experiments. Effective Chinese medicine for-
mulae and herbs include Qianggan Ruanjian decoction
[10] consisting of Radix Angelicae Sinensis, Radix Paeoniae
Alba (Baishao), Radix Salviae Miltiorrhizae (Danshen), Radix
Curcumae  (Yujin),  Herba Patriniae (Baijiangcao),  Fructus
Gardeniae (Zhizi), Radix Rehmanniae Recens (Shengdi), Rhi-
zoma Atractylodis Macrocephalae (Baizhu), Radix Astragali
(Huangqi), Fructus Crataegi (Shanzha) and Herba Artemi-
siae Scopariae (Yinchen). In particular, the effects of Radix
Salviae Miltiorrhizae (Danshen) and Semen Persicae and
their extracts, cucurbitacin B, oleanolic acid, glycyrrhizic
acid and hanfangchin A against liver fibrosis were investi-
gated extensively. (3) Clinical trials and molecular studies
(1990s onwards).
In 2006, the first national guideline on the diagnosis and
treatment of liver fibrosis with integrative medicine was
published [9]. The efficacy of Chinese medicine formulae
against liver fibrosis is being evaluated in multicenter,
randomized controlled clinical trials and the molecular
actions are also being studied. In particular, Fuzheng
Huayu (FZHY) formula has been shown to have efficacy
on liver fibrosis, post-hepatic cirrhosis and the prevention
of hepatic encephalopathy [11-14].
Effects of FZHY on liver fibrosis
FZHY formula is a complex preparation to treat liver fibro-
sis. FZHY consists of six Chinese medicinal herbs, namely
Radix Salvia Miltiorrhizae, Cordyceps (Chongcao),  Semen
Persicae, Gynostemma Pentaphyllammak (Jiaogulan), Pollen
Pini (Songhuafen), Fructus Schisandrae Chinensis (Wuweizi)
(Table 1).
The effects of FZHY on the decompensated cirrhosis
caused by hepatitis B were investigated in clinical studies
[12]. Eighty patients were enrolled and randomly
assigned to the control and treatment groups (40 patients
per group), and received FZHY plus Vitamins B and C, and
Vitamins B and C respectively. The results showed that
FZHY improved liver function parameters, albumin (Alb)
level in particular, while it decreased γ-globin content,
enhanced the plasma ratio of branched chain amino acid
(BCAA)/aromatic amino acid (AAA), increased urine Hyp
excretion, decreased serum laminin (LM) and haluronic
acid (HA) level. FZHY also modulated the immune sys-
Table 1: Composition of Fuzheng Huayu (FZHY)
Herbal components Daily dose (g/60 kg adult)
Radix Salviae Miltiorrhizae 8.0
Fermentation Mycelium Powder 4.0
Fructus Schisandrae Chinensis 2.0
Semen Persicae 2.0
Pollen Pini 2.0
Gynostemma Pentaphyllammak 6.0Chinese Medicine 2009, 4:12 http://www.cmjournal.org/content/4/1/12
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tem, for example, it improved CD3+ and CD4+ counts,
natural killer cell activity and complement 3 (C3) content.
The effects of FZHY on liver fibrosis caused by chronic
hepatitis B were studied in a clinical trial [11,13], in which
95 patients with chronic hepatitis B were randomly
assigned to the treatment (63 patients) and control (32
patients) groups, and received FZHY and Dahuang Zhe-
chong Wan respcetively. The liver function and serological
fibrotic markers were tested before and after treatment
and 12 patients in the treated group were examined with
liver biopsy. The results showed that FZHY markedly
decreased serum alanine aminotransferase (ALT) activities
and total bilirubin. FZHY also significantly improved
serum albumin and A/G ratio, lowered serum monamine
oxidase activities, tissue inhibitor of metalloproteinase-1
(TIMP-1), type III procollagen (P-III-P) and LM and
increased urine Hyp content. The improvement of these
markers except TIMP-1 in treatment group was better than
those in the control. Liver biopsy of seven out of 12
patients showed significantly decreased fibrosis. The
results suggest that FZHY is effective in treating liver fibro-
sis and inflammation caused by chronic hepatitis B.
A multicenter, randomized, double blinded and parallel
controlled (Heluoshugan capsule) clinical study on 216
patients with liver fibrosis caused by chronic hepatitis B
was carried out to evaluate the safety and efficacy of FZHY
[15]. The hepatic histological changes and HBV markers
were examined at weeks 0 and 24 of the treatment. Sero-
logical parameters (HA, LM, P-III-P, IV-C) and liver func-
tion were determined. B ultrasound examination of the
spleen and liver was performed at weeks 0, 12 and 24.
Blood and urine routines, renal function and ECG were
performed before and after treatment. Mean score of
fibrotic stage in experiment group after treatment (1.80)
decreased significantly (P < 0.05) from that before treat-
ment (2.33). There was no significant difference before
(2.11) and after (2.14) treatment in the control. There was
significant difference in reverse fibrosis rate between the
experiment (52%) and control (23.3%) groups in liver
biopsy. FZHY inhibited inflammatory activity signifi-
cantly. Compared to pretreatment, there was a significant
decrease in HA, LM, P-III-P and IV-C content after 12 and
24 weeks of treatment. The difference in HA, LM, P-III-P
and IV-C content between 12, 24 weeks of treatment and
pretreatment in experiment group was significant. The
effect, defined as two out of four parameters are more
than 30% lower than the baseline, was 72.7% and 27.4%
in the experiment and control groups respectively.
Improvement in serum Alb, ALT, aspartate aminotrans-
ferase (AST) and γ-glutamyl transferase (GGT) was seen in
two groups. Marked improvement in GGT and Alb was
seen in experiment group (P < 0.05). The effective rate of
improvement in serum ALT was 72.7% and 59.4% in the
experiment and control groups respectively. There was no
significant difference in blood and urine routines and
ECG before and after treatment. There was also no signif-
icant difference in stable rate in ALT and serological
parameters for liver fibrosis between the experiment and
control groups after 12 weeks' withdrawal. The data show
that FZHY is effective in alleviating liver fibrosis caused by
chronic hepatitis B (Figure 1) and there was no observable
adverse effect.
Recently, we conducted a phase III trial [12] and collec-
tively analyzed the effects of FZHY, on liver fibrosis caused
by chronic hepatitis B. The results show that FZHY is effec-
tive to treat liver fibrosis caused by chronic hepatitis B,
including fibrotic stage S3 with hepatic inflammation,
hypochondriac pain and dry mouth. The dynamic patho-
logical changes in liver, the contents of serum Alb, HA and
P-III-P, GGT activities, prothrombin time (PT), and black-
ish complexion, except the serum LN and IV-C, were all
found significantly improved after treatment [16].
Actions of FZHY against liver fibrosis
Inhibition of HSC activation
Activation of HSC is a key cellular process of liver fibrosis
[17]. Under normal conditions, quiescent HSCs are
located in the hepatic perisinusoidal spaces with vitamin
A storage in their cytoplsamic lipid droplets. Paracrine
activation of HSCs is stimulated by oxidative stress,
inflammatory cytokines and endothelial matrix alterna-
tion. The activated HSCs release cytokines such as TGF-β
and perpetuate the autocrine activation of HSCs. All acti-
vated HSCs increase the capabilities of cell proliferation,
fibrogenesis and contraction, contributing to the overpro-
duction and accumulation of ECM in liver [18].
We observed the effect of FZHY on α-smooth muscle actin
(α-SMA) expression (HSC activation marker) in HSC both
in vivo and in vitro. Liver fibrosis induced by tetrachloride
carbon (CCl4) or dimethylnitrosamine (DMN) in rats was
prophylaxised or treated with FZHY. The results showed
that FZHY decreased α-SMA protein expression in the
fibrotic liver examined by Western blot and immunohis-
tochemical stain, as well as attenuated ECM deposition in
liver (Figure 2).
In an in vitro study, we isolated and cultured primary
HSCs from rats, collected the drug serum [19] from the
rats that took FZHY [20] and incubated the HSCs with
FZHY drug serum. The results showed that the FZHY drug
serum could inhibit α-SMA expression and collagen syn-
thesis in HSCs in a concentration dependent manner (Fig-
ure 3). Both in vivo and in vitro results indicate that FZHY
can inhibit HSC activation and that this action is one of
the action mechanisms of FZHY against liver fibrosis.Chinese Medicine 2009, 4:12 http://www.cmjournal.org/content/4/1/12
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HSCs can be activated by cytokines through autocrine and
paracrine processes. Platelet-derived growth factor-BB
(PDGF-BB) is a proliferative factor and TGF-β1 is a profi-
brogenic cytokine; both play pivot roles in HSC activa-
tion. We found that the FZHY drug serum inhibited the
PDGF-BB-stimulated HSC proliferation and collagen
secretion in a dose dependent manner, in particular type I
collagen (Col-I) secretion and gene expression, and
decreased TGF-β1 expression in activated HSCs (Figure 4).
Furthermore, we collected the conditioned medium after
treatment of activated HSCs with FZHY drug serum (drug
serum treated hepatic stellate cell's conditioned medium,
D-HcCM), and incubated the medium with quiescent
HSCs (freshly isolated). Results showed that the D-HcCM
inhibited HSC spontaneous activation, indicating that
FZHY inhibits HSC via down-regulation of an autocrine
process [19].
Cytokines such as PDGF-BB and TGF-β1 are also secreted
by Kuppfer cells at an early stage of liver injury and simu-
late HSC activation via a paracrine process. We isolated
Kuppfer cells from normal and liver-injured rats and incu-
bated the cells with the FZHY drug serum, collected the
culture medium as Kuppfer cell conditioned medium
(KcCM). We tested the effect of all kinds of conditional
media on quiescent HSC. We found that the control
Effect of FZHY on liver fibrosis in a patient with chronic hepatitis B Figure 1
Effect of FZHY on liver fibrosis in a patient with chronic hepatitis B. The biopsy liver tissues were stained with VG 
before (A) and after (B) treatment. × 100.
 
 
 
 
 
 
 
 
A          B  
Effect of FZHY on α-SMA expression in fibrotic liver Figure 2
Effect of FZHY on α-SMA expression in fibrotic liver. The liver fibrosis was induced with CCl4 in rats. Treatment group 
was administered with FZHY at the start of six-week intoxication, while the control group was given saline; α-SMA expression 
in liver tissue was determined by immunohistochemical stain. (×100).
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medium collected from liver-injured rats had higher con-
centration of TGF-β1 and PDGF-BB than that in the
medium collected from normal rats and increased quies-
cent HSC cell proliferation and Col-I secretion. FZHY drug
serum reduced the TGF-β1 and PDGF contents in Kuppfer
cells from liver-injured rats. Moreover, FZHY drug serum
decreased HSC proliferation and Col-I secretion in com-
parison to the cells treated with the control medium.
These findings suggest that FZHY can inhibit Kuppfer cell
activation and its paracrine effects on HSC activation [21]
(Figure 5).
Besides cytokines, ECM deposition also stimulates HSC
activation, which can regulate cell functions through
integrin pathway. We found that at early stage of liver
injury in DMN-induced fibrotic rats, hepatic fibronectin
(FN) increased and then HSC activated as well as integrin
α5β1 expression and focal adhesion kinase (FAK) phos-
phorylation increased. FZHY decreased FN expression and
reduced integrin α5β1 and FAK phosphorylation [22]. We
coated plastics with FN and planted primarily isolated
HSC on it. Results show that FN stimulates quiescent HSC
activation, but FZHY drug serum inhibits FN stimulates
HSC activation, and this action was associated with the
down-regulation of integrin expression and FAK phos-
phorylation [23], i.e. FZHY inhibits HSC activation via
FN/integrin pathway (Figure 6).
Protection of hepatocytes from oxidative stress and apoptosis
Liver injuries, such as hepatocytic inflammatory necrosis
and apoptosis, are the precursors of liver fibrosis [24]. Free
radicals and oxidative products such as malondialdehyde
(MDA) stimulate HSC activation. Liver peroxidation also
increases matrix metalloproteinases-2/9 (MMP-2/9),
thereby degrading membrane matrix and disrupting
hepatic micro-structure and finally activating HSCs.
Therefore, liver injury is a bridge between liver inflamma-
tion and fibrosis and protecting hepatocytes from oxida-
tive and apoptosis is important in preventing liver
fibrosis.
Effect of FZHY drug serum on collagen secretion from HSC Figure 3
Effect of FZHY drug serum on collagen secretion 
from HSC. The collagen secretion rate was assayed by 
[3H]-Proline incorporation and collagenase digestion; values 
are expressed as mean ± standard deviation (SD) of three 
separate experiments and compared by t test. *P < 0.05 vs. 
the control. 5%, 10% and 20% mean different concentrations 
of sera from rats administered with FZHY (FZHY drug 
serum) or saline (control).
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Effect of FZHY on TGF-β1 expression in activated HSC Figure 4
Effect of FZHY on TGF-β1 expression in activated HSC. Immunocytochemical stain with anti-TGF-β1 (×200). A: HSC 
treated with normal rat serum (control); B: HSC treated with FZHY drug serum.
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CCl4-intoxicated rats had features of hepatocytic fatty
degeneration, liver steatohepatitis and fibrosis. In our
studies [25,26] with CCl4-intoxicated rats, FZHY pro-
tected hepatocytes from degeneration and necrosis,
improved serum liver functionl, inhibited hepatic lipid
peroxidation through improved SOD activity and
decreased MDA content, and decreased liver hydroproline
content for collagen production. We also found that FZHY
lowered MMP-2/9 activities in fibrotic liver during contin-
ued CCl4-intoxication (Figure 7). To confirm FZHY effect
on hepatocyte injury, we isolated and cultured the pri-
mary cultured hepatocytes from rats, induced cell injury
with CCl4, and incubated the cells with FZHY drug serum
for 48 hours. FZHY did improve the recovery of injured
hepatocytes in vitro, indicating that FZHY exerts its anti-
fibrosis effects through protecting hepatocytes from lipid
peroxidation and changes in hepatic micro-structure.
Hepatocytic apoptosis may lead to liver fibrosis. In a
recent study, we induced hepatocytic apoptosis in vivo
through injection of Lipopolysaccharide (LPS) in mice
[27]. FZHY treatment significantly attenuated hepatocytic
apoptosis as indicated by terminal deoxynucleotidyl-
transferase-mediated nick end-labelin (TUNEL) staining,
and regulated caspase-3 activity and apoptotic factors
expression in mitochondria, such as promoting the
expression of anti-apoptotic Bcl-2 and counteracting the
expression of pro-apoptotic Bax (Figure 8). These findings
were also confirmed by in vitro incubation of FZHY drug
serum with apoptotic hepatocytes induced by tumor
necrosis factor α (TNF-α) (Figure 9).
Actions on sinusoidal endothelial cell and hepatic sinusoidal 
capillarization
Hepatic sinusoidal capillarization in endothelial space of
Disse is a key event in liver fibrogenesis. Normally this
space contains the components of a basement membrane
that is low-dense matrix mainly consisting of type IV col-
lagen and laminin and forms a discontinuous endothelial
basement membrane. Sinusoidal endothelial cell (SEC),
which lines inner sinusoid, has a lot of fenestrate. The
structure of hepatic sinusoid serves as a sieve to facilitate
the rapid interchange of material between the blood and
hepatocytes. In early fibrogenesis, the accumulation of
subendothelial matrix, in particular replacement of nor-
mally low-density matrix with high-density ones, and loss
of fenestrate in SEC, would lead to transformation of con-
tinuous subendothelial basement membrane from dis-
continuous one and transition of closed circulation to an
open one, i.e. a process known as "capillarization" [28].
Such capillarization causes hepatocytic dysfunction and
high portal pressure, leading to advanced fibrosis or cir-
rhosis.
Effect of FZHY drug serum treated Kuppfer cell conditioned medium on quiescent HSC proliferation and Col-I secretion Figure 5
Effect of FZHY drug serum treated Kuppfer cell conditioned medium on quiescent HSC proliferation and Col-
I secretion. HSC proliferation was assayed with [3H]TdR incorporation HSC; type I collagen secretion was measured at HSC 
supernatants with ELISA. Values are expressed as mean ± standard deviation (SD) of three separate experiments and com-
pared by ANOVA. *P < 0.05, vs. N-KcCM, #P < 0.05, vs. C-KcCM.
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In our studies [29-32], the DMN-induced rats had high
portal pressure and low interstitial collagenases 13 (MMP-
13). The SEC damage was manifested by increased Factor
VIII related antigen (vWF) expression and serum HA level.
FZHY significantly improved twisting and occlusions of
hepatic sinusoids, and alleviated loss of fenestrate in SEC
and formation of continuous subendothelial basement
membrane. FZHY decreased high portal pressure and liver
fibrosis, and reduced the expression of Factor VIII related
antigen and α-SMA in hepatic sinusoidal wall signifi-
cantly. FZHY improved MMP-13 activity in liver tissue,
through decreasing plasminogen activator inhibitor-1
(PAI-1) and TIMP-1 which are inhibitors of stromelysin
and MMP-13. The results show that FZHY can inhibit and
improve the reversal of hepatic sinusoidal capillarization
and that FZHY's actions are associated with protection of
SEC and inhibition of HSC activation.
Coordinated effects of FZHY and its actions against liver 
fibrosis
The herbs in a Chinese herbal formula may have coordi-
nated effects [33]. We used L16 (215) orthogonal design
(Table 2) and observed the coordinated effect on liver
fibrosis in rats [34].
The fibrotic models were induced by hypodermic injec-
tion of CCl4 plus oral administration of high fat and low
protein food and DMN. The fibrotic rats were randomly
divided into subgroups according to the experiment
design and orally fed with different composition of herbs
from start of CCl4 intoxication or after DMN models were
established. In prophylaxis experiment with CCl4 model,
Semen Persicae was a key factor to decrease hepatic hydrox-
yproline, Radix Salvia Miltiorrhizae had prominent effect
on improving serum Alb and decreasing total bilirubin
level, while Cordyceps and Gynostemma Pentaphyllammak
had a remarkable effect on decreasing serum ALT activity.
These four herbs have coordinated effects for prevention
of liver fibrosis, while Semen Persicae and  Radix Salvia
Miltiorrhizae are the main herbs of FZHY in preventing
liver fibrosis [34].
In the experiments with the DMN model of liver fibrosis,
Cordyceps  and  Gynostemma Pentaphyllammak had strong
effects on reducing hepatic hydroxyproline contents and
attenuating collagen deposition, while Radix Salvia Milti-
orrhizae and Cordyceps Extract piece had significant effects
on improving liver function such as reducing serum ALT
activity. These findings indicate that Cordyceps plays an
important role in reversing liver fibrosis, as a main ingre-
dient of FZHY.
While the active ingredients of FZHY have not been eluci-
dated, we found several effective compounds from the
constituent herbs of FZHY, such as amygdalin from Semen
Persicae, salvianolic acid B (SA-B) from Radix Salvia Milti-
orrhizae. In particular, SA-B against liver fibrosis was
found effective.
Radix Salviae Miltiorrhizae and its active ingredients
Action of Radix Salviae Miltiorrhizae and salvianolic acid B against 
liver fibrosis
In the early 1950s, there were reports on the decoctions
containing  Radix Salviae Miltiorrhizae (Sm) in treating
splenomegaly due to schistosomiasis at advanced stage
[35]. In recent years, this formula has been widely used to
treat chronic hepatitis B and posthepatitic cirrhosis at its
Effect of FZHY on FN and integrin pathway mediators Figure 6
Effect of FZHY on FN and integrin pathway media-
tors. Liver fibrosis was induced by DMN and treated with 
FZHY. Normal: normal rats; Model, model control; FZHY: 
FZHY-treated. Protein expression and FAK phosphorylation 
were checked with Western blot.
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Dynamic changes of MMP2/9 activity and effect of FZHY on  fibrotic liver of CCl4 induced rat Figure 7
Dynamic changes of MMP2/9 activity and effect of 
FZHY on fibrotic liver of CCl4 induced rat. Gelatin 
zymography. Time phases after CCl4 intoxication. N: normal; 
M: model control; FZHY: FZHY-treated.
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early stage. The extract from Sm is now used clinically as
injection formulation for treating chronic hepatitis B. The
liver biopsy tests before and after treatment with Sm injec-
tion revealed that liver fibrosis was improved [36]. The
dynamic ultrasound Doppler examination of the patients
with post-hepatitic cirrhosis revealed that Sm root injec-
tion effectively increased the portal blood flow [37].
SA-B, a major water soluble component in Sm, relieves the
CCl4-induced fibrosis and reverses DMN-induced liver
fibrosis in rats. It prevents liver cell injury, inhibits prolif-
eration of HSCs and collagen production in vitro [38-42].
Therefore, SA-B is one of the active components of Sm
against liver fibrosis.
Between 1996 and 2001, we carried out a randomized
controlled clinical trial to evaluate the clinical efficacy of
SA-B in treating liver fibrosis caused by chronic hepatitis B
[43]. With the randomized, double blinded and double
placebo-controlled method, 60 patients with definite
diagnosis of liver fibrosis caused by hepatitis B were
included, and Interferon-γ (IFN-γ) was used as control
Effect of FZHY on hepatocytes apoptosis in vivo Figure 8
Effect of FZHY on hepatocytes apoptosis in vivo. Acute liver injury with hepatocyte apoptosis was induced by infusion of 
LPS plus D-GalN for six hours in mice. Treatment group was administered with FZHY two days before LPS intoxication, while 
the control was given saline. The apoptotic hepatocytes were stained with TUNEL. (×100).
 
 
 
 
 
 
 
 
Normal    Model  control     FZHY  treated 
Effect of FZHY drug serum on apoptosis in hepatocytes in vitro Figure 9
Effect of FZHY drug serum on apoptosis in hepatocytes in vitro. Primary hepatocytes were isolated from mice and cul-
tured; apoptosis was induced by TNF-α and actinomycin D (Act D) for six hours. Control group was incubated with normal 
rat serum, while treatment group was administered with FZHY drug serum at the same time. Normal control was cultured 
with newborn calf serum without TNF-α and Act D. The cell apoptosis was checked with Annexin V/Propidium Iodide (PI) 
stain and observed under the confocal laser scanning microscopy. Early apoptotic cells were Annexin V positive (green) alone, 
late apoptotic and necrotic cells were both Annexin V and PI positive or PI positive (red) alone respectively. (×630).
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drug. The patients of the treatment group orally took SA-
B tablets (60 mg) or received muscular injection of IFN-γ
(IMU), meanwhile the patients of the control group
received placebos as injection or tablets. The complete
course lasted for 6 months. The histological changes of
liver biopsy specimens before and after treatment were
examined together with the test results of contents of
serum HA, LN, IV-C, P-III-P and liver ultrasound imaging.
The results showed that both SA-B and IFN-γ treatments
improve liver inflammation and fibrosis, but SA-B does
better than IFN-γ. The reversal rates of fibrosis were
36.67% with SA-B and 30.0% with IFN-γ. IFN-γ treatment
showed side effects such as fever, whereas SA-B treatment
did not (Figure 10).
Actions of salvianolic acid B on TGF-β1 in hepatic stellate cell and 
fibrotic liver
Our in vitro studies [44-46] showed that 0.1 μmol/L-10
μmol/L SA-B had no toxic effect on primary cultured
HSCs, but inhibited serum stimulated HSC proliferation
in a dosage dependent manner as indicated by [3H] thym-
ine incorporation. SA-B (1 μmol/L-10 μmol/L) had signif-
icant effects against the biological responses of TGF-β1
stimulated HSCs, including collagen gene expression, α-
SMA and PAI-1 expression. Furthermore, SA-B (1 μmol/L-
10  μmol/L) inhibited the plasmic and nuclear protein
expression of Small Mothers against decapentaplegic
deleted 2/3 (Smad2/3) and significantly inhibited intrac-
ellular phosphorylation of Smad2, decreased type I recep-
tor expression and TβR binding. These results suggest that
the main actions of SA-B against liver fibrosis are to antag-
onize TGF-β1-dependent activation of HSCs by inhibiting
intracellular signal transduction of TGF-β1/Smads in
HSCs.
Conclusion
FZHY has been developed and tested in the past 20 years
as a new Chinese medicine product to treat liver fibrosis.
Although only some of the action mechanisms and active
components of FZHY were discovered and much effort
should be made to improve our scientific understanding,
a high potential of developing new drug products such as
FZHY from Chinese medicine for treating liver fibrosis has
been demonstrated.
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